Susan Catalano

Company: Capsida Biotherapeutics

Job title: Chief Scientific Officer

Seminars:

Advancing Capsida’s Novel Engineered AAV Gene Therapies to the Clinic: Brain-Wide Expression of STXBP1 Corrects Seizure, Cognitive & Motor Haploinsufficiency Phenotypes 11:30 am

Capsida’s high-throughput, automated platform for screening engineered AAV capsids has accelerated the discovery of novel breakthrough capsids from multiple serotypes that cross the BBB following intravenous delivery to efficiently distribute genetic payloads throughout the CNS Presenting overview of Capsida’s program targeting a genetic epilepsy caused by mutations in the STXBP1 gene Preclinical models indicate that…Read more

day: POST-CONFERENCE DELIVERY FOCUS DAY

WORKSHOP A: Designing & Selecting Vectors to Better Traverse the Blood Brain Barrier for your Gene Therapy 9:00 am - 12:00 pm

Strides have been made over the past few years in novel capsid development for neurological gene therapies. However, with a plethora of choices now available for capsid selection, how do you know which capsid will best suit your therapy? Join this workshop to learn: Underpin the importance of capsid selection to compliment your Gene Therapy…Read more

day: DISCOVERY TRACK AM